Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions

Burley, K; Wolf, Julia; Raffoux, Emmanuel; Marks, David I.

doi:10.1038/s41409-017-0038-8

Cited by 4 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the levels of importance of AMP/mTOR-dependent autophagy signaling, adenosine receptor signaling, hormetic ER stress signaling, and inflammasome signaling are gaining relevance to normal hematopoiesis and hematological adverse drug reactions. Very recently, examination of the GATA transcription factor-regulated group of solute carrier transporters demonstrated a nucleoside transporter-dependent differentiation mechanism in erythrocytes [120]. This analysis revealed more than 50 SLC gene cohorts regulated by two GATA transcription factors (GATA1 and/or GATA2) during erythroid differentiation to determine the small molecular composition of erythroid precursors.…”

Section: Summary and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Ali

Raj

Kaur

et al. 2022

Cancers

View full text Add to dashboard Cite

Anticancer nucleoside analogs produce adverse, and at times, dose-limiting hematological toxicities that can compromise treatment efficacy, yet the mechanisms of such toxicities are poorly understood. Recently, cellular nucleoside transport has been implicated in normal blood cell formation with studies from nucleoside transporter-deficient mice providing additional insights into the regulation of mammalian hematopoiesis. Furthermore, several idiopathic human genetic disorders have revealed nucleoside transport as an important component of mammalian hematopoiesis because mutations in individual nucleoside transporter genes are linked to various hematological abnormalities, including anemia. Here, we review recent developments in nucleoside transporters, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleoside drug treatment. Furthermore, we discuss the putative mechanisms by which aberrant nucleoside transport may contribute to hematological abnormalities and identify the knowledge gaps where future research may positively impact treatment outcomes for patients undergoing various nucleoside analog therapies.

show abstract

Section: Summary and Future Perspectivesmentioning

confidence: 99%

“…The primary toxicity that occurred in these patients was hematological toxicity. The frequency of anemia was found to be approximately 37%; thrombocytopenia-8 to 23% [101][102][103][104]; lymphopenia-79% [103,120,121]; and neutropenia-37 to 46% [67,102,132] (Table 2).…”

Section: Hematological Toxicities Of Anticancer Nucleoside Drugsmentioning

confidence: 99%

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Ali

Raj

Kaur

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…T-cell ALL, which is common in adolescents and older patients, is an aggressive neoplasm derived from malignant transformation of lymphoblasts committed to T-cell lineage. Compared to B-cell ALL, it carries poorer prognosis due to: (1) more extensive involvement of bone marrow and extramedullary sites, (2) higher relapse rates even after allogeneic HSCT, and (3) higher incidence of drug resistance which is attributed to aberrant signaling pathways [73][74][75][76][77][78].…”

Section: Hsct In T-cell Allmentioning

confidence: 99%

“…It is indicated in treating relapses post-allogeneic HSCT and in maintenance therapy following transplantation in HR patients [79]. In patients with T-cell ALL relapsing after allogeneic HSCT, the combination of nelarabine and donor lymphocyte infusions (DLIs) may provide long-term disease control and survival [77].…”

Section: Hsct In T-cell Allmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Era of Novel Agents and Targeted Therapies

Ka¹

2018

J Stem Cell Biol Transplant

View full text Add to dashboard Cite

The outcomes of adult patients with acute lymphoblastic leukemia have improved significantly due to the recent advances in diagnostics and in therapeutic interventions. The adoption of pediatric chemotherapeutic regimens in adolescents and young adults, the availability of several novel and targeted therapies, and the provision of safer modalities of stem cell transplants have yielded higher response rates and improved survival.This review article will be a recent update on the role of hematopoietic stem cell transplantation in adults with acute lymphoblastic leukemia in the era of novel agents and targeted therapies. Various modalities of stem cell therapies in different subtypes of acute lymphoblastic leukemia in addition to various modalities of novel therapies will also be discussed thoroughly.

show abstract

Nelarabine

2018

Reactions Weekly

View full text Add to dashboard Cite

Long-term survival following post-allograft relapse of T-cell acute lymphoblastic leukaemia: a novel approach using nelarabine and donor lymphocyte infusions

Cited by 4 publications

References 14 publications

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Era of Novel Agents and Targeted Therapies

Nelarabine

Contact Info

Product

Resources

About